We haven't done that type of analysis ourselves. We have seen studies that would suggest that there would potentially be an economic impact, perhaps upwards of $4 billion a year, but those aren't studies that we've done ourselves.
One of the things that I would emphasize to the committee is that, if we have the correct data, we can model a lot of this ahead of time. We would certainly advocate, not just for an investment in data and analysis, but also in the willingness of the various partners to provide the data. I mentioned that our data is strong around public programs; therefore, it's strong for looking at seniors and low-income populations with much less rich data on privately funded drug programs and some of the costs associated with that.
The other thing we have opportunities to do is to bring data together or link data to look at the relationship between use of pharmaceuticals and visits to hospitals, etc. We can do more studies, such as the one I mentioned, with a stronger information base. A lot of these questions can be analyzed.